Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Colorectal Neoplasms 9Stomach Neoplasms 6Neoplasm Metastasis 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Solid Tumor 3Neoplasms 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lung Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Small Cell Lung Cancer Extensive Stage 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Muscle Invasive Bladder Cancer 1

Interventions

Rituximab 55Cyclophosphamide 41Lenalidomide 25Vincristine 23Doxorubicin 22Prednisone 21Etoposide 16ibrutinib 12Gemcitabine 12fludarabine phosphate 10fludarabine 10Peripheral Blood Stem Cell Transplantation 10Carboplatin 10Bendamustine Hydrochloride 10Ifosfamide 9Filgrastim 8polatuzumab vedotin 7obinutuzumab 7Oxaliplatin 7Mycophenolic Acid 7Methotrexate 6Cyclosporine 6venetoclax 5tafasitamab 5Vorinostat 5Radiotherapy 5R-CHOP protocol 5Prednisolone 5Melphalan 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, Large B-Cell, Diffuse × tislelizumab × Clear all
NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

BeOne Medicines

Phase 1/2 Completed
97 enrolled 43 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

BeiGene

Phase 1/2 Completed
53 enrolled 17 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡